

Lars Forsgren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5486726/publications.pdf>

Version: 2024-02-01

40
papers

2,101
citations

304368

22
h-index

315357

38
g-index

40
all docs

40
docs citations

40
times ranked

4433
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
2	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.4	152
3	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 1175.	4.5	148
4	Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population-based study. <i>Movement Disorders</i> , 2010, 25, 341-348.	2.2	111
5	Early predictors of mortality in parkinsonism and Parkinson disease. <i>Neurology</i> , 2018, 91, e2045-e2056.	1.5	111
6	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 549-560.	1.5	99
7	The robust electrochemical detection of a Parkinson's disease marker in whole blood sera. <i>Chemical Science</i> , 2012, 3, 3468.	3.7	72
8	Exploring causality of the association between smoking and Parkinson's disease. <i>International Journal of Epidemiology</i> , 2019, 48, 912-925.	0.9	70
9	Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 41-47.	1.1	66
10	Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea. <i>JAMA Internal Medicine</i> , 2015, 175, 1278.	2.6	64
11	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 34-39.	1.7	60
12	Deep brain stimulation in the caudal zona incerta versus best medical treatment in patients with Parkinson's disease: a randomised blinded evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 710-716.	0.9	59
13	Weight gain and increased central obesity in the early phase of Parkinson's disease. <i>Clinical Nutrition</i> , 2014, 33, 1132-1139.	2.3	57
14	The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal. <i>Neuroscience Letters</i> , 2017, 658, 48-52.	1.0	57
15	Immunochemical Detection of α -Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1170-1176.	1.7	52
16	Fine mapping and resequencing of the PARK16 locus in Parkinson's disease. <i>Journal of Human Genetics</i> , 2015, 60, 357-362.	1.1	51
17	NMR metabolomics of cerebrospinal fluid distinguishes between Parkinson's disease and controls. <i>Neuroscience Letters</i> , 2015, 594, 36-39.	1.0	50
18	Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden. <i>Neurobiology of Aging</i> , 2016, 45, 212.e5-212.e11.	1.5	50

#	ARTICLE	IF	CITATIONS
19	A Generic Method for Design of Oligomer-Specific Antibodies. PLoS ONE, 2014, 9, e90857.	1.1	38
20	Î±-synuclein~lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15226-15235.	3.3	33
21	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 202-210.	1.1	27
22	Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism. PLoS ONE, 2014, 9, e113387.	1.1	25
23	NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson~s disease and control subjects. Metabolomics, 2016, 12, 1.	1.4	23
24	Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimer's and Dementia, 2018, 14, 1293-1301.	0.4	23
25	Activities of daily living in Parkinson's disease: Time/gender perspective. Acta Neurologica Scandinavica, 2020, 141, 168-176.	1.0	23
26	Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients. Blood Cells, Molecules, and Diseases, 2018, 68, 86-92.	0.6	21
27	Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. Neurology, 2021, 96, e1036-e1044.	1.5	17
28	Moist smokeless tobacco (Snus) use and risk of Parkinson~s disease. International Journal of Epidemiology, 2017, 46, dyw294.	0.9	14
29	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	1.1	12
30	Fractional Anisotropy and Mean Diffusion as Measures of Dopaminergic Function in Parkinson~s Disease: Challenging Results. Journal of Parkinson's Disease, 2017, 7, 129-142.	1.5	11
31	Balance and mobility in patients with newly diagnosed Parkinson~s disease ~ a five-year follow-up of a cohort in northern Sweden. Disability and Rehabilitation, 2020, 42, 770-778.	0.9	11
32	PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study. Journal of the Neurological Sciences, 2017, 381, 278-284.	0.3	8
33	General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study. Parkinsonism and Related Disorders, 2019, 62, 98-104.	1.1	7
34	Could miRNA expression changes be a reliable clinical biomarker for Parkinson~s disease?. Neurodegenerative Disease Management, 2013, 3, 455-465.	1.2	6
35	Low frequency of GCH1 and TH mutations in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 109-111.	1.1	5
36	Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson~s Disease Cohorts. Journal of Parkinson's Disease, 2021, 11, 1569-1578.	1.5	5

#	ARTICLE	IF	CITATIONS
37	How long for epilepsy remission in the <sc>ILAE</sc> definition?. <i>Epilepsia</i> , 2017, 58, 1486-1487.	2.6	4
38	The Effects of Working Memory Updating Training in Parkinsonâ€™s Disease: A Feasibility and Single-Subject Study on Cognition, Movement and Functional Brain Response. <i>Frontiers in Psychology</i> , 2020, 11, 587925.	1.1	4
39	Cross-camera comparison of ROI-based semi-quantitative ¹²³ I-IBZM SPECT data in healthy volunteers using an anthropomorphic phantom for calibration. <i>Acta Radiologica</i> , 2013, 54, 549-556.	0.5	0
40	Rare variants in dementia genes and Parkinsonâ€™s disease. <i>European Journal of Human Genetics</i> , 2016, 24, 1661-1662.	1.4	0